We observed the HER3 mutation T355I to be oncogenic in the absence of HER2 over-expression in ER+ breast cancer, a novel finding and clinically relevant as this mutation has been identified in 4 ER+ breast cancer patients. The gene discussed is ESR1; the disease is breast cancer.